Literature DB >> 23064071

[Multimodality therapy containing hepatic arterial infusion chemotherapy for liver metastasis of esophageal cancer-a case report].

Masahiko Ikebe1, Masayuki Kitamura, Genkichi Saitoh, Hirofumi Hasegawa.   

Abstract

A 60-year-old man who had had a subtotal esophagectomy for esophageal cancer was given the diagnosis of hepatic metastases ten months after his operation. Systemic chemotherapy was stopped after a short time because of adverse effects. He refused to continue any other systemic chemotherapy. He was going to receive hepatic arterial infusion chemotherapy(HAI)with the prospect of having less systemic effects. Combination regimen of 5-FU with low-dose CDDP was administered for five days every three weeks. Hepatic metastases decreased markedly without adverse effects. The tumor was well controlled for two years until occlusion of hepatic artery. Radiation therapy and liver resection were performed subsequently. The patient lived more than 4 years after the diagnosis of hepatic metastases. HAI can be a treatment of choice for esophageal cancer when metastasis is limited to the liver.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23064071

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

Review 1.  Interventional Therapy of Esophageal Cancer.

Authors:  Aiwu Mao
Journal:  Gastrointest Tumors       Date:  2016-08-27

2.  Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer.

Authors:  Jing Xu; Donghui Lu; Li Zhang; Jian Li; Guoping Sun
Journal:  Cancer Med       Date:  2019-10-14       Impact factor: 4.452

Review 3.  The role of surgical treatment in isolated organ recurrence of esophageal cancer-a systematic review of the literature.

Authors:  Dimitrios Schizas; Ioannis I Lazaridis; Demetrios Moris; Aikaterini Mastoraki; Lazaros-Dimitrios Lazaridis; Diamantis I Tsilimigras; Nikolaos Charalampakis; Theodore Liakakos
Journal:  World J Surg Oncol       Date:  2018-03-14       Impact factor: 2.754

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.